Related Experiment Video

Updated: Jun 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Antithrombotic therapy in the secondary prevention of stroke]

E V Mel'nikova, M I Kadinskaia, D V Gerasimenko

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |June 2, 2011
    PubMed

    Insights

    Secondary prevention of ischemic stroke involves antithrombotic or anticoagulant therapy. Improved platelet function testing is crucial due to increasing antiplatelet resistance, enhancing evidence-based stroke prevention.

    Area of Science:

    • Neurology
    • Cardiology
    • Clinical Medicine

    Context:

    • Secondary prevention of ischemic events following ischemic stroke is critical.
    • Current guidelines recommend antithrombotic therapy or anticoagulant therapy with INR monitoring.
    • Transient Ischemic Attack (TIA) management is also addressed within this context.

    Purpose:

    • To review evidence-based recommendations for secondary prevention strategies post-ischemic stroke.
    • To highlight the need for improved diagnostics in evaluating platelet function.
    • To address the challenge of antiplatelet therapy resistance.

    Summary:

    • The review presents recommendations for antithrombotic and anticoagulant therapies for secondary stroke prevention, emphasizing INR monitoring.
    • It notes that patients not requiring anticoagulants should undergo antiplatelet therapy.
    • A significant challenge identified is the rising incidence of resistance to antiplatelet agents.

    Impact:

    • The findings underscore the necessity for rapid and accurate platelet function evaluation.
    • Current laboratory diagnostic methods for platelet function require improvement to meet evidence-based medicine standards.
    • Developing reliable, standardized laboratory methods is essential for optimizing patient care and secondary stroke prevention.

    More Related Videos

    Prehospital Thrombolysis: A Manual from Berlin05:52

    Prehospital Thrombolysis: A Manual from Berlin

    Published on: November 26, 2013

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...